NeuroVive and Lund University Collaboration Receives Grant for Liver Cancer Research
LUND, Sweden, Oct. 18, 2017 /PRNewswire/ -- NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF), the mitochondrial medicine company, today announced that NeuroVive andRamin Massoumi at Lund University have been granted 2.5 MSEK from the Swedish Foundation for Strategic Research (SFF...
NeuroVive's Collaborator, the Children's Hospital of Philadelphia Awarded NIH Grant to Study NVP015 Against Chemical Threats
LUND, Sweden, Oct. 6, 2017 /PRNewswire/ -- NeuroVive Pharmaceutical AB (NASDAQ Stockholm: NVP, OTCQX: NEVPF), the mitochondrial medicine company, today announced that its research collaboration partner the Children's Hospital ofPhiladelphia (CHOP) has received a two-year grant, #1R21NS103826-01f ...
NeuroVive Appoints Daniel Schale as Director of Communications
LUND, Sweden, Oct. 4, 2017 /PRNewswire/ -- NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF), the mitochondrial medicine company, today announced the appointment ofDaniel Schale as Director of Communications. Daniel will report to CFOCatharina Johansson. Daniel Schale will be res...
NeuroVive and Yungjin Pharm Start Clinical Development in Genetic Mitochondrial Disease
LUND, Sweden and SEOUL, South Korea, June 27, 2017 /PRNewswire/ -- NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF) and Yungjin Pharm Corporation Ltd (South Korea Stock Market, KRX 003520) today announced that the clinical phase I study of KL1333 has started in Korea and that...
NeuroVive Receives Research Grant From Vinnova for Development of the NVP015 Genetic Mitochondrial Disease Project
LUND, Sweden, June 1, 2017 /PRNewswire/ -- NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF) today announced that the company receives close to 1 million SEK in a research grant from Swedish innovation agency, Vinnova, for developing a new treatment for genetic mitochondrial diseas...
NeuroVive to Continue NeuroSTAT® Clinical Development After Positive Outcome in Preclinical and Clinical TBI Studies
LUND, Sweden,, May 23, 2017 /PRNewswire/ -- NeuroVive Pharmaceutical AB(Nasdaq Stockholm: NVP, OTCQX: NEVPF) today announced positive results from clinical and preclinical studies with its drug NeuroSTAT® for the prevention of the sequelae of traumatic brain injury (TBI). The company is now prep...
NeuroVive Pharmaceutical AB Interim Report January - March 2017
STOCKHOLM, May 18, 2017 /PRNewswire/ -- Broadened project portfolio Business operations Significant events January-March 2017 * Strong inhibitory effects demonstrated in human hepatocellular carcinoma cells and in an experimental model of liver cancer with the Company's new generation of s...
NeuroVive Invitation to Conference Call and Web Cast on in-licensing Agreement With Yungjin Pharm
LUND, Sweden, May 2, 2017 /PRNewswire/ -- NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF) ("NeuroVive") invites to a conference call and webcast tomorrow,3 May 2017, at 2:00 pm CEST, to present the in-licensing agreement with Yungjin Pharm that was announced this morning. Erik ...
NeuroVive in-licenses a Genetic Mitochondrial Disease Clinical Stage Project From Yungjin Pharm
LUND, Sweden and SEOUL, South Korea, May 2, 2017 /PRNewswire/ -- NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF) and Yungjin Pharm Corporation Ltd (South Korea Stock Market, KRX 003520) today jointly announced that they have entered into a global licensing agreement on Yungjin P...
NeuroVive Presents Preclinical Findings of NV556 in NASH Showing Confirmatory Anti-fibrotic Effects
LUND, Sweden, April 20, 2017 /PRNewswire/ -- NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF) ("NeuroVive")today announced positive preclinical results demonstrating anti-fibrotic effects with NV556, the company's preclinical compound for non-alcoholic steatohepatitis (NASH), in ...
NeuroVive's Lead NASH Project to be Presented at The International Liver Congress(TM)
LUND, Sweden, April 5, 2017 /PRNewswire/ -- NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF),the mitochondrial medicine company, today announced that an abstract with preclinical data related to the company's lead project for non-alcoholic steatohepatitis (NASH) has been accepted...
Number of Shares and Votes in NeuroVive Pharmaceutical AB (publ)
LUND, Sweden, March 31, 2017 /PRNewswire/ -- NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF), the mitochondrial medicine company, today announced an increase of the number of shares and votes in NeuroVive of 23,328. This is a result of a performed subscription options program (...
NeuroVive Pharmaceutical AB Publishes 2016 Annual Report
LUND, Sweden, March 23, 2017 /PRNewswire/ --
NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF), the
mitochondrial medicine company, today announced that the English version of the
Annual report for 2016 is now available on the company's website
www.neurovive.com
Notice of Annual General Meeting of Shareholders in NeuroVive Pharmaceutical AB
LUND, Sweden, March 23, 2017 /PRNewswire/ -- The Board of Directors of NeuroVive Pharmaceutical AB (publ) has issued a notice to the Annual General Meeting, which is to take place onThursday, April 27, 2017, at 4 pm at Medicon Village, Scheelevagen 2 in Lund, Sweden. Please see the attached not...
NeuroVive Appoints Recognized Scientific Advisors and Enters Research Agreements in NASH and Hepatocellular Carcinoma
LUND, Sweden, Feb. 22, 2017 /PRNewswire/ -- NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF),the mitochondrial medicine company, today announced two new research agreements and the appointment of ProfessorPhilippe Gallay, PhD, and Professor Massimo Pinzani, MD, PhD, FRCP, as scie...
NeuroVive Pharmaceutical AB Year End Report January - December 2016
STOCKHOLM, Feb 21, 2017 /PRNewswire/ -- Important steps forward and new research collaborations Business operations Important events October – December 2016 * The development of CicloMulsion for acute kidney injury was discontinued and as a consequence, the value of the subsidiary NeuroVive A...
NeuroVive's new Generation of Sanglifehrin-based Compounds Demonstrate Potent Inhibitory Effects on Human Hepatocellular Cancer Cells
LUND, Sweden, Feb. 2, 2017 /PRNewswire/ -- NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF), the mitochondrial medicine company, presents preclinical data from a new generation of sanglifehrin-based compounds with potent inhibitory effects on hepatocellular carcinoma (HCC) cells...
NeuroVive Redirects Research Resources From Asian Subsidiary to Parent
Lund, Sweden, Jan 25, 2017 /PRNewswire/ -- NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF), the mitochondrial medicine company, today announced that itsTaiwan-based subsidiary's research resources and activities will be redirected to the parent company NeuroVive Pharmaceutical ...
NeuroVive Signs Mitochondrial Medicine Research Agreement With US key Opinion Leader
LUND, Sweden, Jan. 23, 2017 /PRNewswire/ -- NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF),today announces that NeuroVive has signed a preclinical collaboration agreement with the Children's Hospital ofPhiladelphia (CHOP) andMarni J. Falk, M.D., a US key opinion leader in the m...
NeuroVive Presents Positive Preclinical Data in Hepatocellular Cancer at HCC Summit
LUND, Sweden, Jan. 19, 2017 /PRNewswire/ -- NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF),the mitochondrial medicine company, today announced that an abstract with novel preclinical cancer data related to the company's sanglifehrin-based compounds has been accepted for present...
